Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Adapalene and benzoyl peroxide

Drug class: Retinoid

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Adapalene and benzoyl peroxide key facts

Drug class
Retinoid
Used for
EPIDUO FORTE is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. (source)
Prescription or over the counter
Prescription (Rx) · some products also sold over the counter
Generic available
Yes
Typical pharmacy cost
$0.6474 per gram (adapalene 0.3% · benzoyl peroxide 2.5%; NADAC)
Latest FDA recall
None listed

Sources: FDA label (October 24, 2024); FDA NDC Directory (October 30, 2026); CMS NADAC (November 4, 2026); FDA enforcement reports (October 27, 2026). Not medical advice.

Quick answers

What is Adapalene and benzoyl peroxide used for?
The FDA-approved label (Epiduo Forte, Galderma Laboratories, L.P., October 24, 2024) says: “EPIDUO FORTE is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. EPIDUO FORTE, is a combination of adapalene, a retinoid, and benzoyl peroxide and is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Adapalene and benzoyl peroxide?
The “Adverse Reactions” section of the FDA label (Epiduo Forte, Galderma Laboratories, L.P., October 24, 2024) begins: “The most common adverse reactions (incidence ≥1%) are skin irritation, eczema, atopic dermatitis and skin burning sensation.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Adapalene and benzoyl peroxide have a boxed warning?
No. None of the 19 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Adapalene and benzoyl peroxide?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Adapalene and benzoyl peroxide been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Adapalene and benzoyl peroxide?
13 companies list prescription products of Adapalene and benzoyl peroxide in the FDA NDC Directory, including Bryant Ranch Prepack, Sun Pharmaceutical Industries, Inc. and Padagis Israel Pharmaceuticals Ltd.

What Adapalene and benzoyl peroxide is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

EPIDUO FORTE is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. EPIDUO FORTE, is a combination of adapalene, a retinoid, and benzoyl peroxide and is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older.

— FDA label: Epiduo Forte, Galderma Laboratories, L.P., effective October 24, 2024. Read the full label on DailyMed →

Label quoted: the one for the most common form (gel, topical), Epiduo Forte, Galderma Laboratories, L.P.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 19 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 19 FDA labels for this medicine have a boxed warning.

Adapalene and benzoyl peroxide side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The most common adverse reactions (incidence ≥1%) are skin irritation, eczema, atopic dermatitis and skin burning sensation.

Read more of this section

(6) To report SUSPECTED ADVERSE REACTIONS, contact Galderma Laboratories, L.P. at 1-866-735-4137 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience The following adverse reactions are discussed in greater detail elsewhere in the labeling: Hypersensitivity [see Warnings and Precautions (5.1)] Skin Irritation/Contact Dermatitis [see Warnings and Precautions (5.3)] Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. During the randomized, double-blind, vehicle- and active-controlled clinical trial, 217 subjects were exposed to EPIDUO FORTE. A total of 197 subjects with acne vulgaris, 12 years and older, were treated once daily for 12 weeks. Adverse reactions reported within 12 weeks of treatment in at least 1% of subjects treated with EPIDUO FORTE and for which the rate with EPIDUO FORTE exceeded the rate for the vehicle are presented in Table 1: Table 1. Adverse Reactions Occurring in ≥ 1% of Subjects with Acne Vulgaris in a 12-week Clinical Trial EPIDUO FORTE (N=217) Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% (N=217) Vehicle (N=69) Skin irritation 4% <1% 0% Eczema 1% 0% 0% Dermatitis atopic 1% 0% 0% Skin burning sensation 1% 0% 0% Local tolerability evaluations presented in Table 2, were conducted at each trial visit in the clinical trial by assessment of erythema, scaling, dryness, and stinging/burning, which peaked at Week 1 of therapy and decreased thereafter. Table 2. Incidence of Local Cutaneous Irritation in 12-week Clinical Trial in Subjects with Acne Vulgaris Maximum Severity During Treatment End of Treatment Severity (Final Score) Moderate Severe Moderate Severe EPIDUO FORTE (N=213) Erythema 20% 1% 4% <1% Scaling 17% 1% 1% <1% Dryness 15% 2% 3% <1% Stinging/Burning 19% 6% 1% 1% Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% (N=212) Erythema 15% 1% 2% <1% Scaling 12% <1% 2% 0% Dryness 13% 1% 2% 0% Stinging/Burning 14% 9% 3% 0% Vehicle (N=68) Erythema 6% 1% 1% 0% Scaling 6% 0% 1% 0% Dryness 4% 1% 1% 0% Stinging/Burning 3% 1% 0% 0% 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of EPIDUO FORTE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and subcutaneous tissue disorders: sunburn, blister (including vesicles and bullae), pruritus, hyperpigmentation and hypopigmentation..

Table from the label
EPIDUO FORTE (N=217)Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% (N=217)Vehicle (N=69)
Skin irritation4%<1%0%
Eczema1%0%0%
Dermatitis atopic1%0%0%
Skin burning sensation1%0%0%

— FDA label: Epiduo Forte, Galderma Laboratories, L.P., effective October 24, 2024. This is part of the section. Read the full label on DailyMed →

Adapalene and benzoyl peroxide dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

For topical use only. EPIDUO FORTE is not for oral, ophthalmic, or intravaginal use. Apply a thin layer of EPIDUO FORTE to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). Wash hands after application as EPIDUO FORTE may bleach hair or colored fabrics. Avoid the eyes, lips and mucous membranes. For topical use only EPIDUO FORTE is not for oral, ophthalmic or intravaginal use.

Read more of this section

(2) Apply a thin layer of EPIDUO FORTE to affected areas of the face and/or trunk once daily after washing. (2) Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). (2) Avoid the eyes, lips, and mucous membranes. (2)

— FDA label: Epiduo Forte, Galderma Laboratories, L.P., effective October 24, 2024. Read the full label on DailyMed →

Adapalene and benzoyl peroxide in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Available pharmacovigilance data with EPIDUO FORTE use in pregnant women are insufficient to establish a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with the combination gel.

Read more of this section

Adapalene gel, 0.3% Available data from clinical trials with adapalene gel 0.3% use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of adapalene to pregnant rats and rabbits during organogenesis at dose exposures 41 and 81 times, respectively, the human exposure at the maximum recommended human dose (MRHD) of 2 g resulted in fetal skeletal and visceral malformations (see Data). Benzoyl peroxide gel, 2.5% The systemic exposure of benzoyl peroxide is unknown. Based on published literature, benzoyl peroxide is rapidly metabolized to benzoic acid (an endogenous substance), which is eliminated in the urine. Hence, maternal use is not expected to result in fetal exposure of the drug. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data No malformations were observed in rats treated with oral adapalene doses of 0.15 to 5.0 mg/kg/day, up to 8 times the MRHD of 2 grams of EPIDUO FORTE based on a mg/m2 comparison. However, malformations were observed in rats and rabbits when treated with oral doses of ≥ 25 mg/kg/day adapalene (41 and 81 times the MRHD, respectively, based on a mg/m2 comparison). Findings included cleft palate, microphthalmia, encephalocele, and skeletal abnormalities in rats and umbilical hernia, exophthalmos, and kidney and skeletal abnormalities in rabbits. Dermal adapalene embryofetal development studies in rats and rabbits at doses up to 6.0 mg/kg/day (9.7 and 19.5 times the MRHD, respectively, based on a mg/m2 comparison) exhibited no fetotoxicity and only minimal increases in skeletal variations (supernumerary ribs in both species and delayed ossification in rabbits).

— FDA label: Epiduo Forte, Galderma Laboratories, L.P., effective October 24, 2024. Read the full label on DailyMed →

When Adapalene and benzoyl peroxide should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

EPIDUO FORTE is contraindicated in patients with a history of hypersensitivity reactions to benzoyl peroxide or any components of the formulation in EPIDUO FORTE. EPIDUO FORTE is contraindicated in patients with a history of hypersensitivity reactions to benzoyl peroxide or any components of the formulation in EPIDUO FORTE. (4)

— FDA label: Epiduo Forte, Galderma Laboratories, L.P., effective October 24, 2024. Read the full label on DailyMed →

Forms and how it is given

Dosage formsGel
RouteTopical
Prescription products19 in the FDA NDC Directory
Brand namesEpiduo Forte

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Adapalene and benzoyl peroxide, by strength and form
Strength and formGeneric or brandPharmacies pay
adapalene 0.1% · benzoyl peroxide 2.5%
gel
Generic $0.3873 per gram
adapalene 0.3% · benzoyl peroxide 2.5%
gel
Generic $0.6474 per gram
adapalene 0.3% · benzoyl peroxide 2.5%
gel
Brand: Epiduo Forte $14.97 per gram

NADAC list of November 4, 2026; these prices took effect between September 23, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA207917
EPIDUO FORTE
Galderma LabsJuly 15, 2015 2, latest April 27, 2022
2022: Labeling · 2022: Labeling

Generic approvals (10)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)829539, 1663745, 1663747
SPL set ID of the quoted labelf4e5d381-098a-4c93-9ff0-002cae46daac
FDA labels (SPL)19
FDA applicationsNDA207917, 10 ANDA
Active ingredients (FDA)ADAPALENE / BENZOYL PEROXIDE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Epiduo Forte, Galderma Laboratories, L.P., effective October 24, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers